Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S WINER

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Cancer Discovery|January 11, 2022
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesEva J Schaefer, Helen C Wang, Hannah Q Karp, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Cancer Discovery|January 11, 2022
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesEva J Schaefer, Helen C Wang, Hannah Q Karp, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Blood|November 4, 2022
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S Garcia, Yael Flamand, Livius Penter, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Pageof 12